Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 6/20 | 0.46 |
| ▸ | DRD3 | P35462 | 6/20 | 0.46 |
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29512901 | 1.00 | MMP12 (0.51) | MMP12CYP11B1CYP11B2PARP1KIF11 | |
| SCHEMBL277585 | 0.86 | MMP12 (0.65) | MMP12PARP1CA9ALDH1A1MAPT | |
| SCHEMBL30343101 | 0.86 | MMP12 (0.65) | MMP12PARP1CA9ALDH1A1MAPT | |
| SCHEMBL6297092 | 0.83 | CYP11B1 (0.64) | MMP12CYP11B1CYP11B2KIF11PDE3B | |
| SCHEMBL6302322 | 0.83 | ALDH1A1 (0.51) | MMP12CYP11B1CYP11B2PARP1KIF11 | |
| SCHEMBL6297460 | 0.83 | CYP11B1 (0.44) | MMP12CYP11B1CYP11B2PARP1KIF11 | |
| SCHEMBL28575263 | 0.83 | CA9 (0.51) | MMP12CYP11B1CYP11B2KIF11PDE3B | |
| SCHEMBL6295828 | 0.80 | CYP11B1 (0.44) | MMP12CYP11B1CYP11B2PARP1KIF11 | |
| SCHEMBL6295568 | 0.80 | ATM (0.50) | MMP12CYP11B1CYP11B2KIF11PDE3B | |
| SCHEMBL9437792 | 0.79 | DRD4 (0.53) | MMP12CYP11B1CYP11B2PARP1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | claimed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | claimed |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | claimed |
| JP-2003508387-A | — | — | 2003-03-04 | — | — | JP | claimed |
| EP-1212303-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2001016108-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | claimed |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-09 | — | — | US | disclosed |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-02-13 | — | — | US | disclosed |
| US-12054483-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-08-06 | — | — | US | disclosed |
| CN-117924247-A | Triazole derivative with liver cancer cell activity inhibiting function, and preparation method and application thereof | 河南科技大学 | 2024-04-26 | — | — | CN | disclosed |
| EP-3532474-B1 | 4,5-ANNULATED 1,2,4-TRIAZOLONES | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| CN-114921391-B | 4, 5-cyclic 1,2, 4-triazolones | 拜耳股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| WO-1992004345-A1 | 6- or 7- (2-IMINO-2-IMIDAZOLIDINE)-1,4-BENZOXAZINES AS ALPHA ADRENERGIC AGENTS | ALLERGAN, INC. (US) | 1992-03-19 | — | — | WO | disclosed |
| US-5091528-A | Antiglaucoma, antidiarrhea agents, diuretics, vasoconstrictors | ALLERGAN, INC. (US) | 1992-02-25 | — | — | US | disclosed |
| US-5077401-A | Herbicides | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1991-12-31 | — | — | US | disclosed |
| WO-1991013941-A1 | WATER-INSOLUBLE AZO DYES, THEIR MANUFACTURE AND USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-09-19 | — | — | WO | disclosed |
| US-5026831-A | Water-insoluble disazo colorants having hetero-bicyclic methylene-active compounds as coupling component | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-06-25 | — | — | US | disclosed |
| US-4902335-A | Benzo-fused cyclic compounds | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1990-02-20 | — | — | US | disclosed |
| EP-0296416-A1 | Benzo-anellated cyclic compounds | NIHON BAYER AGROCHEM K.K. (JP) | 1988-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | MMP12 2347/4885CYP11B1 1588/4885CYP11B2 1572/4885 |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC1 | MMP12 3902/4885CYP11B1 427/4885CYP11B2 430/4885 |
| US-12054483-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK2, CLK1, CLK3 | MMP12 2754/4885CYP11B1 2737/4885CYP11B2 2795/4885 |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | MMP12 2754/4885CYP11B1 2737/4885CYP11B2 2795/4885 |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | MMP12 2574/4885CYP11B1 31/4885CYP11B2 38/4885 |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | MMP12 3389/4885CYP11B1 2534/4885CYP11B2 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.